Skip to main content
Top
Published in:

01-11-2024 | Checkpoint Inhibitors | Research

Usefulness of urine dipstick test in the management of adverse events associated with immune checkpoint inhibitors

Authors: Keishiro Izumi, Tomokazu Iyoda, Atsuko Yokota, Masahito Kanno, Masahiro Hoshi, Emi Tokuda, Eisaku Sasaki, Kenya Kanazawa, Junko Kuroda, Shigehira Saji

Published in: Supportive Care in Cancer | Issue 11/2024

Login to get access

Abstract

Purpose

The usefulness of urine dipstick tests (UDTs) in patients with diabetes has been reported. The aim of the present study was to investigate the utility of self-performed UDTs and patient diaries in the management of impaired glucose tolerance, one of the adverse events of immune checkpoint inhibitors (ICIs).

Methods

Patients receiving ICIs underwent self-checks with UDTs twice a week for up to 6 months. Pharmacists checked the results at every patient visit, and by phone every 3 months. The primary endpoint was to prospectively assess whether symptoms recorded in patient diaries and UDTs could reduce unscheduled hospital admissions due to impaired glucose tolerance. The secondary endpoint was the correlation between the symptoms in the patient diaries and UDT results.

Results

A total of 112 patients were enrolled in the study. Out of the 3197 planned self-UDTs, 3128 (97.8%) were performed. Forty-four patients (39.3%) were admitted to the hospital, two (1.8%) of whom were admitted due to abnormal glucose tolerance, with one having a positive UDT. There were 46 unscheduled outpatient visits (41.1%), of which five (4.5%) were due to abnormal glucose tolerance symptoms and four were due to a positive UDT. The correlation between descriptions of fatigue or dry mouth in the patient diaries and positive glucose UDTs was 52.4% in sensitivity and 62.4% in specificity.

Conclusion

Self-monitoring of symptoms and self-performing of UDTs could not reduce the emergency hospitalization rate. However, this approach could be effective in the objective monitoring of patient status, especially regarding glucose intolerance occurrences.
Appendix
Available only for authorised users
Literature
3.
go back to reference Zamanzad B (2009) Accuracy of dipstick urinalysis as a screening method for detection of glucose, protein, nitrites and blood. East Mediterr Health J Sep-Oct 15(5):1323–1328 Zamanzad B (2009) Accuracy of dipstick urinalysis as a screening method for detection of glucose, protein, nitrites and blood. East Mediterr Health J Sep-Oct 15(5):1323–1328
7.
go back to reference Castro-Balado A, Tourís-Lores M, Lema-Oreiro M, Bernárdez-Ferrán B, Zarra-Ferro I (2022) TELEA-Farmacia: pharmaceutical care by telepharmacy to oncology patients from a hospital pharmacy service. Farm Hosp. 46(7):5–14PubMed Castro-Balado A, Tourís-Lores M, Lema-Oreiro M, Bernárdez-Ferrán B, Zarra-Ferro I (2022) TELEA-Farmacia: pharmaceutical care by telepharmacy to oncology patients from a hospital pharmacy service. Farm Hosp. 46(7):5–14PubMed
8.
go back to reference Begnoche BR, David Butler C, Carson PH, Darr A, Jenkins MT, Le T, McDaniel RB, Mourad H, Shipman CJ, Stratton TP, Tran K, Wong KK (2022) ASHP statement on telehealth pharmacy practice. Am J Health Syst Pharm 79(19):1728–1735. https://doi.org/10.1093/ajhp/zxac188 Begnoche BR, David Butler C, Carson PH, Darr A, Jenkins MT, Le T, McDaniel RB, Mourad H, Shipman CJ, Stratton TP, Tran K, Wong KK (2022) ASHP statement on telehealth pharmacy practice. Am J Health Syst Pharm 79(19):1728–1735. https://​doi.​org/​10.​1093/​ajhp/​zxac188
11.
go back to reference Qin Q, Patel VG, Wang B, Mellgard G, Gogerly-Moragoda M, Zhong X, Parikh AB, Leiter A, Gallagher EJ, Galsky MD, Oh WK, Tsao C-K (2020) Type, timing and patient characteristics associated with immune-related adverse event development in patients with advanced solid tumors treated with immune checkpoint inhibitors. J Clin Oncol. 38(15suppl):e15160 Qin Q, Patel VG, Wang B, Mellgard G, Gogerly-Moragoda M, Zhong X, Parikh AB, Leiter A, Gallagher EJ, Galsky MD, Oh WK, Tsao C-K (2020) Type, timing and patient characteristics associated with immune-related adverse event development in patients with advanced solid tumors treated with immune checkpoint inhibitors. J Clin Oncol. 38(15suppl):e15160
13.
go back to reference Stamatouli AM, Quandt Z, Perdigoto AL, Clark PL, Kluger H, Weiss SA, Gettinger S, Sznol M, Young A, Rushakoff R, Lee J, Jeffrey A. Bluestone, Mark Anderson, Kevan C. Herold (2018) Collateral damage: insulin-dependent diabetes induced with checkpoint inhibitors. Diabetes. 67(8):1471–1480. https://doi.org/10.2337/dbi18-0002 Stamatouli AM, Quandt Z, Perdigoto AL, Clark PL, Kluger H, Weiss SA, Gettinger S, Sznol M, Young A, Rushakoff R, Lee J, Jeffrey A. Bluestone, Mark Anderson, Kevan C. Herold (2018) Collateral damage: insulin-dependent diabetes induced with checkpoint inhibitors. Diabetes. 67(8):1471–1480. https://​doi.​org/​10.​2337/​dbi18-0002
20.
go back to reference Jackson K, Letton C, Maldonado A, Bodiford A, Sion A, Hartwell R, Graham A, Bondarenka C, Uber L (2019) A pilot study to assess the pharmacy impact of implementing a chemotherapy-induced nausea or vomiting collaborative disease therapy management in the outpatient oncology clinics. J Oncol Pharm Pract. 25(4):847–854. https://doi.org/10.1177/1078155218765629CrossRefPubMed Jackson K, Letton C, Maldonado A, Bodiford A, Sion A, Hartwell R, Graham A, Bondarenka C, Uber L (2019) A pilot study to assess the pharmacy impact of implementing a chemotherapy-induced nausea or vomiting collaborative disease therapy management in the outpatient oncology clinics. J Oncol Pharm Pract. 25(4):847–854. https://​doi.​org/​10.​1177/​1078155218765629​CrossRefPubMed
Metadata
Title
Usefulness of urine dipstick test in the management of adverse events associated with immune checkpoint inhibitors
Authors
Keishiro Izumi
Tomokazu Iyoda
Atsuko Yokota
Masahito Kanno
Masahiro Hoshi
Emi Tokuda
Eisaku Sasaki
Kenya Kanazawa
Junko Kuroda
Shigehira Saji
Publication date
01-11-2024
Publisher
Springer Berlin Heidelberg
Published in
Supportive Care in Cancer / Issue 11/2024
Print ISSN: 0941-4355
Electronic ISSN: 1433-7339
DOI
https://doi.org/10.1007/s00520-024-08928-y

Other articles of this Issue 11/2024

Supportive Care in Cancer 11/2024 Go to the issue
SPONSORED

Recent advances in the use of CAR T-cell therapies in relapsed/refractory diffuse large B-cell lymphoma and follicular lymphoma

  • Webinar | 01-10-2024 | 12:30 (CEST)

In this webinar, Professor Martin Dreyling and an esteemed international panel of CAR T-cell therapy experts discuss the latest data on the safety, efficacy, and clinical impact of CAR T-cell therapies in the treatment of r/r DLBCL and r/r FL.

Please note, this webinar is not intended for healthcare professionals based in the US and UK.

Sponsored by:
  • Novartis Pharma AG
Chaired by: Prof. Martin Dreyling
Developed by: Springer Healthcare
Get a reminder for the on-demand version